Drug intelligence / Profile preview

OMV-WT

Development stage
Preclinical
Modality
Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Vaccines & Immunotherapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Nanoparticles → Drug Delivery Systems, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration
Intravenous
01

Overview

OMV-WT (Wild-Type Outer Membrane Vesicles) are naturally occurring, nano-sized proteoliposomes secreted by Gram-negative bacteria, such as *Escherichia coli*. These vesicles are composed of a lipid bilayer containing various bacterial proteins, lipids, and pathogen-associated molecular patterns (PAMPs), most notably lipopolysaccharides (LPS). In the context of oncology research, OMV-WT is utilized for its intrinsic immunomodulatory properties, as it can activate the innate immune system primarily through the Toll-like receptor 4 (TLR4) pathway. This activation promotes the recruitment and infiltration of CD8+ T cells into the tumor microenvironment and stimulates the release of interferon-gamma (IFN-γ), which can inhibit tumor growth and potentially induce ferroptosis in cancer cells. OMV-WT serves as a foundational wild-type platform for genetic engineering to create targeted delivery systems, such as those designed to cross the blood-brain barrier for glioblastoma immunotherapy.

Other names
Wild-type outer membrane vesiclesWT-OMVBacterial outer membrane vesicles
02

Targets

TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on OMV-WT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on OMV-WT.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call